"GoPubMed is a sort of an intelligent Google for biomedical specialists", explained Dr. Michael Alvers, CEO and co-founder of Transinsight. "The search engine saves time and so accelerates research significantly."
"Biomedical researchers have to be familiar with a huge number of publications", noted Professor Schroeder, Transinsight's Chief Scientific Officer and co-founder. "The PubMed database currently contains 15 million biomedical publications that have to be assessed by research groups." "Researchers in the biotech and pharmaceutical industries spend an average of 12,4 hours a week searching for relevant information", added Dr. Alvers.
GoPubMed can search literature repositories, Web sites, intranets and desktops. It indexes results and thus allows users to explore a large body of results in a structured manner. In contrast to classical search engines, GoPubMed can answer questions using its background knowledge in molecular biology, medicine, drug development and food science. To illustrate this point, a search for aspirin inhibits on a classical search engine returns a large number of unstructured results that do not answer the user's original question. On the other hand, a search with GoPubMed reveals that the most frequently mentioned pathway for aspirin inhibits is the cyclo-oxygenase pathway.
Professor Schroeder stressed: "GoPubMed is intelligent and presents the search results in a way that is specifically linked to the interests of a particular research group." Thanks to its groundbreaking and competitive product, the young company has already won its first corporate customer: Unilever in the United Kingdom. Explaining why Unilever decided to purchase the software, Dr. Cecilia Eyre remarked: "GoPubMed helps us to quickly screen the vast literature for hidden gems and to discover trends in science."
With exciting commercial prospects, the start-up company has also been quick to attract investment. This past January, it was announced that Transinsight had received 500.000 euro of seed funding from Germany's recently established High-Tech-Gründerfonds and a further undisclosed sum from a private investor in Hamburg.
Indeed, such are the high expectations for Transinsight, that the firm was very recently crowned as one of only three "Lighthouse projects of the High-Tech-Gründerfonds" by Michael Glos, German Federal Minister for Economic Affairs and Technology.
For more information you can contact Dr. Michael R. Alvers, CEO, Transinsight GmbH, Tatzberg 47-51, D-01307 Dresden, Germany, Tel.: +49-351-46340059, Fax: +49-351-46340061, or visit the Transinsight GmbH Web site.
This article has been reprinted from the IST Results Web site.